AdcoTx is developing a novel therapeutic to improve first‑line treatment options for colorectal cancer patients worldwide.

AdcoTx is a single‑asset biotech startup translating University of Cambridge oncology research into a novel therapeutic for colorectal cancer (CRC).

The virtual company’s lead asset is an antibody–drug conjugate (ADC) targeting LGR5, a well‑validated marker associated with tumour growth. Currently in late‑stage pre‑clinical development, the asset has demonstrated in vivo proof of principle, with activity against tumour cells.

With CRC set to become a $50 billion opportunity by 2032, AdcoTx is focusing on achieving a Phase I exit milestone with pharma.

AILA Biotech is developing a CNS-targeted gene delivery platform that enables ultra-low-dose viral therapies for chronic neuroinflammatory diseases.

AILA Biotech’s next‑generation Adeno-associated virus (AAV) gene delivery platform is designed specifically for diseases of the central nervous system (CNS).

Current AAV approaches often require very high doses, cause liver toxicity and are too expensive to scale. AILA’s platform enables precise, CNS‑targeted delivery of neurotherapeutics at ultra‑low doses, 5,000–10,000x lower AAV doses than traditional gene therapy, reducing systemic exposure and manufacturing costs.

Emerging from immunology and gene therapy research at the University of Cambridge, the technology is being developed to support disease‑modifying treatments for chronic neuroinflammation, with primary progressive multiple sclerosis (PPMS) as the first indication.

Auralytica creates holographic hydrogel sensors that provide real‑time, low‑cost molecular data with a first market to improve food quality, safety and monitoring.

Auralytica is a deep‑tech company developing holographic hydrogel sensors for real‑time molecular sensing. The technology offers a low‑cost, dye‑free and electronics‑free approach to monitoring quality and safety across food and beverage supply chains.

Auralytica’s first applications focus on in‑package monitoring, providing continuous insight into freshness and spoilage to reduce waste and improve safety.

Emerging from materials and chemistry research, the company is working towards a new generation of intelligent indicators that could redefine how quality information is communicated, including the future of use‑by dates.

Cambridge Cryogenics is building ultra-low-temperature solid-state refrigerators that sit at the heart of quantum computing, quantum communication and AI data centres.

Cambridge Cryogenics designs and manufactures ultra‑low‑temperature solid‑state refrigeration systems for quantum science and technology.

Its compact milliKelvin platforms support quantum computers, sensors, communication devices and advanced materials research, with deployments across research and industrial settings worldwide. Built on patented core technology, the systems offer reliability, scalability and integration with emerging quantum hardware.

Alongside its established research markets, the company is exploring hardware development for applications across adjacent sectors to diversify into emerging cryogenic markets, including medical, space and energy.

Cosysense uses AI agents and digital twins to optimise HVAC systems in commercial buildings, reducing energy costs, emissions and operational inefficiencies.

Cosysense delivers AI‑native control systems for heating, ventilation and air conditioning in commercial buildings. By combining real‑time sensor data, building management systems and digital twins, the platform enables continuous, automated optimisation of building performance.

AI agents automate systems every 15 minutes, balancing energy use, comfort and operational stability. Cosysense’s approach reduces electricity costs and carbon emissions while preventing performance drift common in legacy HVAC systems, improving overall energy efficiency. The proprietary technology is designed to integrate with existing infrastructure, making advanced building intelligence accessible without complex retrofitting.

Neela Biotech produces carbon‑negative aviation fuel by combining synthetic biology, AI and existing biogas infrastructure at competitive cost.

Neela Biotech is building a scalable pathway to carbon‑negative fuels using controlled microbial upcycling. By leveraging existing biogas infrastructure, its proprietary Controlled Microbial Upcycling (CMU) platform converts waste streams into renewable platform chemicals that can be used as drop‑in feedstocks for aviation fuel and other industries.

Advances in AI-driven synthetic biology are used to optimise bioprocess performance and scale. Neela’s approach avoids competition with food, land or water resources and is designed for rapid deployment, offering a practical route to decarbonising aviation while working within established industrial systems.

Satorus Group builds AI agents that automate data collection, analysis and reporting workflows for intelligence and investigation teams.

Satorus Group develops AI agents designed to support intelligence investigations by automating complex information workflows. Its platform ‘Sidney’ scans across open, deep and alternative data sources to identify digital footprints, extract relevant information and structure analysis through natural‑language queries.

By reducing manual research and report preparation, Satorus enables investigators to focus on judgment and decision‑making rather than data handling. The system is designed to integrate into existing intelligence processes, producing outputs that can be repeatedly queried before being formulated into an intelligence report in a format tailored to organisational requirements.

Senesys.Bio is developing precision nanomedicine platforms to selectively deliver senolytic therapies for fibrotic and age‑related diseases.

Senesys.Bio is a University of Cambridge spinout developing a novel nanomedicine platform designed to selectively target and eliminate senescent cells, which drive chronic inflammation, fibrosis and tissue degeneration.

Its proprietary NanoJAGGS™ technology enables targeted delivery of senolytic drugs to diseased cells, addressing safety and selectivity issues that have limited earlier approaches.

The company’s initial focus is on idiopathic pulmonary fibrosis, with broader potential across ageing‑related conditions. By solving the delivery challenge, Senesys.Bio aims to unlock a new class of disease‑modifying therapies.